Aleve: profile and news
NCCN Announces Important Updates to Ovarian Cancer Clinical ... 06 Mar 2006
The regimens include gemcitabine (Gemzar, Lilly)/carboplatin (Paraplatin, Bristol Myers-Squibb) and carboplatin/paclitaxel (Taxol, Bristol Myers-Squibb). ... - Genetic Engineering News,
Millennium and Johnson & Johnson Pharmaceutical Research & ... 06 Mar 2006
...trial results of VELCADE in NSCLC include: * Interim survival data from a Phase II study of VELCADE in combination with gemcitabine and carboplatin in newly ... - Yahoo! News (press release)
American Pharmaceutical Partners Receives FDA Approval for ... Feb 17, 2006
...that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carboplatin Injection (liquid ... - International News Service,
Addition of Ellence® to Standard Chemotherapy Does Not Improve ... Mar 2, 2006
...of Clinical Oncology, the addition of the chemotherapy agent Ellence® (epirubicin) to the standard chemotherapy regimen of Paraplatin® (carboplatin) and Taxol ... - Cancer Consultants (press release),
APP gets FDA approval for new dose of cancer drug Feb 21, 2006
By Staff Writer. American Pharmaceutical Partners has received approval from the FDA to begin marketing carboplatin injection in a 600mg multi-dose vial. ... - Pharmaceutical Business Review
InterMune Discontinues Ovarian Cancer Trial With Actimmune ... Feb 3, 2006
GRACES was a phase 3 trial comparing carboplatin plus paclitaxel (standard of care chemotherapy) combined with Actimmune to carboplatin plus paclitaxel alone ... - DG News
American Pharma net up; gets OK for generic ovarian cancer drug Feb 17, 2006
...company received approval from the Food and Drug Administration for its abbreviated new drug application for the liquid form of its Carboplatin injection in a ... - MarketWatch
Gemcitabine Adds Benefit to Lung Cancer Chemotherapy Feb 23, 2006
...with metastatic non-small-cell lung cancer with good performance status and no relevant comorbidities treated with paclitaxel, carboplatin plus gemcitabine in ... - Cancerpage.com,
Q&A: What to Know About IP Chemotherapy Feb 13, 2006
I want to see if there is a less toxic chemotherapy to give patients. I personally think that IP carboplatin has tremendous appeal. ... - CancerWise
OXiGENE Reports Fourth Quarter and Fiscal Year 2005 Operational ... Mar 1, 2006
Platinum Resistant Ovarian Cancer OXiGENE announced a Phase II clinical trial evaluating CA4P in combination therapy with carboplatin and paclitaxel--a widely ... - Genetic Engineering News,
Generic ovarian cancer drug approved Feb 17, 2006
Squibb's Paraplatin. APP said it expects to begin marketing the 600 mg multi-dose vial of carboplatin in the near future. Sales ... - United Press International
InterMune Discontinues Ovarian Cancer Trial Feb 2, 2006
GRACES was a Phase III trial comparing carboplatin plus paclitaxel (standard of care chemotherapy) combined with Actimmune(R) to carboplatin plus paclitaxel ... - PR Newswire (press release),
InterMune Halts All Cancer Research Into Actimmune Feb 3, 2006
The study compared the combination of Actimmune with the standard regimen of carboplatin and paclitaxel to the two chemo agents alone in advanced ovarian cancer ... - BioWorld Online (subscription),
Survival Benefit Linked to Estrogen in Women Treated With XYOTAX ... Feb 15, 2006
...(CTI) (Nasdaq and MTAX: CTIC) presented updated results of a phase II study of XYOTAX in combination with carboplatin among 35 women and 39 men with advanced ... - PR Newswire (press release),
Survival Benefit Linked to Estrogen in Women Treated With XYOTAX Feb 15, 2006
...(CTI) presented updated results of a phase II study of XYOTAX in combination with carboplatin among 35 women and 39 men with advanced non-small cell lung ... - PharmaLive.com (press release),
Drugs maker sets sights on world market Feb 22, 2006
...been sub-scale. Core oncology products such as carboplatin, methotrexate and paclitaxel had lifted sales and earnings. Dr Soursac ... - The Age,
Coley Pharmaceutical Group Reports Fourth Quarter and Full Year ... Feb 23, 2006
...efficacy and safety of CPG 7909 (now known as PF-3512676) administered in combination with standard-of-care chemotherapy (paclitaxel/carboplatin or gemcitabine ... - MSN Money
American Pharma gets OK for chemo drug Feb 17, 2006
The approval covers a 600 milligram multi-dose vial of injectable carboplatin, the active ingredient in Bristol-Myers Squibb's Paraplatin. ... - BusinessWeek
Mayne Pharma pleased with performance Feb 21, 2006
...said the underlying performance of Mayne Pharma in the first half had been very pleasing, with core oncology products like carboplatin, methotrexate and ... - The Age,
Mayne in the red for first half Feb 22, 2006
...been pleasing. Core oncology products like carboplatin, methotrexate and paclitaxel had increased in sales and earnings. Sales for ... - Sydney Morning Herald,
Bayer and partner launch Phase 3 trial for lung cancer treatment Feb 17, 2006
The study has the Nexavar (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non ... - Boston Mass High Tech,
Merck KGaA Receives EMEA Positive Opinion for Erbitux in Head and ... Feb 23, 2006
In a phase 3 study of 442 patients, Erbitux combined with standard chemotherapy (either cisplatin plus 5-fluorouracil or carboplatin plus 5-fluorouracil) is ... - DG News
ImClone advances Erbitux in three types of cancer Feb 20, 2006
...neck cancer study has enrolled 442 patients with recurrent and/or metastatic head and neck cancer who were randomized to receive cisplatin/carboplatin plus 5 ... - Pharmaceutical Business Review
BCIRG 006 Shows Trastuzumab (Herceptin) Improves Disease-free ... Feb 20, 2006
...presented this three-arm Breast Cancer International Research Group (BCIRG) 006 adjuvant trial that compared a docetaxel with carboplatin and trastuzumab (DCT ... - DG News
[ Business Briefs ] Feb 20, 2006
APP also announced it received US Food and Drug Administration approval for chemotherapy drug Carboplatin, the generic equivalent of Bristol-Myers Squibb Co ... - International News Service,
Sequential High-Dose Chemotherapy with Stem Cell Support Promising ... Feb 21, 2006
The first course of treatment was with high-dose Platinol® (carboplatin), the second with Hycamptin® (topotecan) and Vepesid® (etoposide) and the third with ... - Cancer Consultants (press release),
Bayer and Onyx commence phase III Nexavar trial Feb 20, 2006
...have initiated a phase III clinical trial studying Nexavar tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in ... - Pharmaceutical Business Review
Phenoxodiol Modulates Apoptotic Pathways in Cancer Cells Feb 23, 2006
Pretreatment of epithelial ovarian carcinoma cells with phenoxodiol sensitized them to chemotherapy with carboplatin, paclitaxel, and gemcitabine by lowering ... - Cancerpage.com,
Study Confirms Better Quality of Life with Paraplatin® than ... Feb 7, 2006
Treatment of ovarian cancer with the chemotherapy drugs Paraplatin® (carboplatin) and Taxol® (paclitaxel) results in better quality of life than treatment ... - Cancer Consultants (press release),
Early Chemotherapy Improves Outcomes for Mesothelioma Feb 24, 2006
Approximately half of the patients then received immediate MVP (mitomycin, vinblastine, cisplatin, or carboplatin), while the other half did not receive MVP ... - Cancer Consultants (press release),
Study Confirms Better Quality of Life with Paraplatin® than ... Feb 7, 2006
Researchers from Austria and Germany have reported that a regimen of Paraplatin® (carboplatin) and Taxol® (paclitaxel) is associated with a better quality of ... - Cancer Consultants (press release),
Merck KGaA Receives EMEA Positive Opinion for Erbituxin Head and ... Feb 23, 2006
In a Phase III study of 442 patients, Erbitux combined with standard chemotherapy (either cisplatin plus 5-fluorouracil or carboplatin plus 5-fluorouracil) is ... - PharmaLive.com (press release),
Telik Announces Fourth Quarter and 2005 Year End Financial Results ... Feb 9, 2006
The ASSIST-3 trial was initiated to evaluate the combination of TELCYTA plus carboplatin in second-line platinum refractory or resistant ovarian cancer. ... - Yahoo! News (press release)
German shares close higher as Wall Street gains; Henkel, TUI led ... Feb 16, 2006
...are launching a phase III trial of their drug Nexavar to treat non-small cell lung cancer in combination with chemotherapeutic agents carboplatin and paclitaxel ... - Forbes
UPDATE 1-Bayer, Onyx begin lung cancer test of Nexavar Feb 16, 2006
The trial -- which involves use of Nexavar tablets in combination with standard chemotherapy drugs carboplatin and paclitaxel -- is based on favorable results ... - Reuters
Onyx, Bayer begin Phase III study of Nexavar Feb 16, 2006
...lung cancer. The 900-patient trial uses Nexavar tablets in combination with the chemotherapy drugs carboplatin and paclitaxel. In ... - East Bay Business Times,
(PRN) - Loudeye Corp. to Announce Year End and Fourth Quarter 2005 ... Feb 17, 2006
...for ADHD ... [+. PRN) - American Pharmaceutical Partners Receives FDA Approval for Carboplatin Injection, 600 mg ... [+. PRN) - Media ... - Bolsamania.com,
Bayer, Onyx on phase 3 lung cancer trial Feb 16, 2006
The study, enrolling about 900 patients, will compare the effects of Nexavar taken in combination with two chemotherapy agents, carboplatin and paclitaxel, to ... - United Press International
ImClone Systems Announces Complete Enrollment of Several Studies ... Feb 16, 2006
The EXTREME study has enrolled 442 patients with recurrent and/or metastatic head and neck cancer who were randomized to receive cisplatin/carboplatin plus 5 ... - Genetic Engineering News,
Lung Cancer Drug Pipeline Update Lists All 243 Drugs for Lung ... Feb 16, 2006
...erosion and three major chemotherapy drugs go off patent before 2012, Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli ... - Genetic Engineering News,
Cell Therapeutics: hoping for a rich performance Feb 9, 2006
...to penetrate given stiff competition from Sanofi-Aventis' Taxotere and Eli Lilly's Gemzar, which are routinely combined with cisplatin or carboplatin and form ... - Pharmaceutical Business Review
IP Chemotherapy Encouraged for Ovarian Cancer Feb 13, 2006
The “debulking� is followed with administration of both a platinum drug [cisplatin (Platinol®) or carboplatin (Paraplatin®)] and a taxane drug ... - CancerWise
ImClone Systems Announces Complete Enrollment of Several Studies ... Feb 16, 2006
The EXTREME study has enrolled 442 patients with recurrent and/ormetastatic head and neck cancer who were randomized to receivecisplatin/carboplatin plus 5-FU ... - Finanzen.net,
Cancer drug more effective in women than men Feb 17, 2006
Updated results of a phase II study of Xyotax in combination with carboplatin among 35 women and 39 men with advanced non-small cell lung cancer (NSCLC ... - Pharmaceutical Business Review
Metastatic Melanoma Responds to Taxol® and Paraplatin® Feb 16, 2006
Reference: Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. ... - Cancer Consultants (press release),
Early Chemotherapy Improves Outcomes for Mesothelioma Feb 9, 2006
...the patients then received immediate chemotherapy consisting of the regimen referred to as MVP (mitomycin, vinblastine, cisplatin, or carboplatin), while the ... - Cancer Consultants (press release),
Gemzar® May Improve Results of Taxol®/Paraplatin® Regimen for ... Feb 9, 2006
Researchers from Italy have reported that the addition Gemzar® (gemcitabine) to Taxol (paclitaxel)/Paraplatin (carboplatin) improves survival of patients with ... - Cancer Consultants (press release),
